News stories about Genocea Biosciences (NASDAQ:GNCA) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Genocea Biosciences earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.7082714334355 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

Genocea Biosciences (NASDAQ:GNCA) traded down 3.31% on Friday, hitting $1.75. The company had a trading volume of 2,523,351 shares. The firm has a 50-day moving average price of $4.03 and a 200-day moving average price of $5.27. The firm’s market capitalization is $50.09 million. Genocea Biosciences has a 12-month low of $1.13 and a 12-month high of $7.29.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.08). On average, equities research analysts anticipate that Genocea Biosciences will post ($1.92) earnings per share for the current fiscal year.

A number of research analysts have issued reports on GNCA shares. Needham & Company LLC raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Monday, July 24th. Cowen and Company reaffirmed a “buy” rating and issued a $10.00 price target on shares of Genocea Biosciences in a report on Tuesday, September 26th. ValuEngine raised Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Stifel Nicolaus cut Genocea Biosciences from a “buy” rating to a “hold” rating and cut their price target for the company from $15.00 to $2.50 in a report on Monday, September 25th. Finally, Zacks Investment Research raised Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $10.77.

TRADEMARK VIOLATION WARNING: “Genocea Biosciences (GNCA) Receives Daily Media Impact Score of 0.14” was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at

In related news, CFO Jonathan Poole sold 45,000 shares of the company’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $6.00, for a total transaction of $270,000.00. Following the completion of the sale, the chief financial officer now directly owns 84,247 shares in the company, valued at approximately $505,482. The sale was disclosed in a filing with the SEC, which is available through this link. 6.70% of the stock is owned by corporate insiders.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Insider Buying and Selling by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.